A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug

Day One Biopharmaceuticals appears to be living up to its namesake of altering pediatric cancer care from day one, unveiling positive initial data for its brain tumor drug that saw its share price double on Monday morning.